Remember what the ultimate goal is! Pass all trials and gain FDA approval. Selling shares to pay for the trials is what a public company does. Don't be confused. Since May 2014 to May 2016 Leo has sold about 14 million shares to fund a $hit ton of trials and bring 3 very robust products several phases closer to FDA approval.
I doubt it. There was only about 66-67 k shares in blocks over 5k in size. What's your source? And do you mean "Leo" as an individual or the Co.? If it was the Co selling treasury stock, it would have to be filed with the SEC and you'll see it in the next 10Q and this dilution is minor. For my part, while I don't like dilution, I'd rather not see a development Co taking on long term debt with sales still off a ways. My 2 cts.